검색어 : 통합검색[Anderson Denise G..]
총 146건 중 146건 출력
, 15/15 페이지
-
141
- Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study
- Brown, Jennifer R.; Desikan, Sai Prasad; Nguyen, Bastien; Won, Helen; Tantawy, Shady I.; McNeely, Samuel; Marella, Narasimha; Ebata, Kevin; Woyach, Jennifer A.; Patel, Krish; Tam, Constantine S.; Eyre, Toby A.; Cheah, Chan Y.; Shah, Nirav N.; Ghia, Paolo; Jurczak, Wojciech; Balbas, Minna; Nair, Binoj; Abada, Paolo; Wang, Chunxiao; Wang, Ying (Denise); Roeker, Lindsey E.; Gandhi, Varsha; Wierda, William G.; 1Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; 2The Ohio State University Comprehensive Cancer Center, Columbus, OH; 3Loxo@Lilly, Indianapolis, IN; 3Loxo@Lilly, Indianapolis, IN; 4MD Anderson Cancer Center, Houston, TX; 5Eli Lilly and Company, Indianapolis, IN; 3Loxo@Lilly, Indianapolis, IN; 3Loxo@Lilly, Indianapolis, IN; 2The Ohio State University Comprehensive Cancer Center, Columbus, OH; 6Swedish Cancer Institute, Seattle, WA; 7Alfred Health and Monash University, East Melbourne, Australia; 8Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom; 9Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; 10Medical College of Wisconsin, Milwaukee, WI; 11Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; 12Maria Skłodowska - Curie National Research Institute of Oncology, Krak&oac; (Blood, v.142, 2023, pp.326-326)
-
142
- Evaluation of drug tolerability as a function of toxicity and quality of life in patients enrolled on I-SPY2.
- Basu, Amrita B.; Umashankar, Saumya; Wolf, Denise M.; Chay, Hannah; Abikoye, Abigail; Brown, Thelma; Heditsian, Diane; Brain, Susie; Hieken, Tina J.; Ruddy, Kathryn Jean; Tevis, Sarah; Blaes, Anne Hudson; Lo, Shelly S.; Nanda, Rita; Yau, Christina; Melisko, Michelle E.; Cella, David; Esserman, Laura; Rugo, Hope S.; Hershman, Dawn L.; University of California, San Francisco Department of Surgery, San Francisco, CA; University of California, San Francisco, San Francisco, CA; University of California, San Francisco, San Francisco, CA; University of California, San Francisco, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Susan G. Komen, Birmingham, AL; University of California, San Francisco, San Francisco, CA; UCSF Breast Science Advocacy Core, Palo Alto, CA; Mayo Clinic - Department of Surgical Oncology, Rochester, MN; Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Minnesota Masonic Cancer Center, Minneapolis, MN; Loyola University Medical Center, Maywood, IL; University of Chicago Medicine, Chicago, IL; University of California, San Francisco, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Dept. of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chi; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.42, 2024, pp.11113-11113)
-
143
- Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
- Mato, Anthony R.; Pagel, John M.; Coombs, Catherine C.; Shah, Nirav N.; Lamanna, Nicole; Munir, Tahla; Lech-Marań da, Ewa; Eyre, Toby A.; Woyach, Jennifer A.; Wierda, William G.; Cheah, Chan Yoon; Cohen, Jonathon B.; Roeker, Lindsey E.; Patel, Manish R.; Fakhri, Bita; Barve, Minal A.; Tam, Constantine S.; Lewis, David John; Gerson, James N.; Alencar, Alvaro J.; Ujjani, Chaitra S.; Flinn, Ian W.; Sundaram, Suchitra; Ma, Shuo; Jagadeesh, Deepa; Rhodes, Joanna M; Taylor, Justin; Abdel-Wahab, Omar; Ghia, Paolo; Schuster, Stephen J.; Wang, Denise; Nair, Binoj; Zhu, Edward; Tsai, Donald; Davids, Matthew S.; Brown, Jennifer R.; Jurczak, Wojciech; Memorial Sloan Kettering Cancer Center, New York, NY; Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Medical College of Wisconsin, Milwaukee, WI; Columbia University Medical Center, New York-Presbyterian/Columbia University Medical Center, New York, NY; Department of Haematology, St James's University Hospital, Leeds, United Kingdom; Institute of Hematology and Transfusion Medicine, Warsaw, Poland; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; Winship Cancer Institute, Emory University, Atlanta, GA; Memorial Sloan Kettering Cancer Center, New York, NY; Flori; (Blood, v.138, 2021, pp.391-391)
-
144
- Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
- Bidard, Franç ois-Clé ment; Michiels, Stefan; Riethdorf, Sabine; Mueller, Volkmar; Esserman, Laura J; Lucci, Anthony; Naume, Bjørn; Horiguchi, Jun; Gisbert-Criado, Rafael; Sleijfer, Stefan; Toi, Masakazu; Garcia-Saenz, Jose A; Hartkopf, Andreas; Generali, Daniele; Rothé , Franç oise; Smerage, Jeffrey; Muinelo-Romay, Laura; Stebbing, Justin; Viens, Patrice; Magbanua, Mark Jesus M; Hall, Carolyn S; Engebraaten, Olav; Takata, Daisuke; Vidal-Martí nez, José ; Onstenk, Wendy; Fujisawa, Noriyoshi; Diaz-Rubio, Eduardo; Taran, Florin-Andrei; Cappelletti, Maria Rosa; Ignatiadis, Michail; Proudhon, Charlotte; Wolf, Denise M; Bauldry, Jessica B; Borgen, Elin; Nagaoka, Rin; Carañ ana, Vicente; Kraan, Jaco; Maestro, Marisa; Brucker, Sara Yvonne; Weber, Karsten; Reyal, Fabien; Amara, Dominic; Karhade, Mandar G; Mathiesen, Randi R; Tokiniwa, Hideaki; Llombart-Cussac, Antonio; Meddis, Alessandra; Blanche, Paul; Institut Curie, UVSQ and Paris Saclay University, Saint Cloud, France; Gustave Roussy, Villejuif, France; Universitä tsklinikum Hamburg-Eppendorf, Hamburg, Germany; Universitä tsklinikum Hamburg-Eppendorf, Hamburg, Germany; University of California at San Francisco, San Francisco, CA; MD Anderson Cancer Center, Houston, TX; Oslo University Hospital, Oslo, Norway; Gunma University Hospital, Gunma, Japan; Hospital Arnau de Vilanova, Valencia, Spain; Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Kyoto University Hospital, Kyoto, Japan; Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain; Women’s Health Center, University of Tuebingen, Tuebingen, Germany; Women Cancer Centre, University of Trieste, ASST of Cremona, Cremona, Italy; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Complejo Hospitalario Universitario, Santiago de Compostela, Sp; (Journal of the National Cancer Institute: JNCI, v.110, 2018, pp.560-567)
-
145
- International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
- Binkley, Michael Sargent; Flerlage, Jamie E.; Savage, Kerry J.; Akhtar, Saad; Steiner, Raphael; Zhang, Xiao-Yin; Dickinson, Michael; Prica, Anca; Major, Ajay; Hendrickson, Peter G.; Hopkins, David; Ng, Andrea; Casulo, Carla; Baron, Jonathan; Roberts, Kenneth B.; Al Kendi, Jalila; Balogh, Alex; Ricardi, Umberto; Torka, Pallawi; Specht, Lena; De Silva, Ravindu; Pickard, Keir; Blazin, Lindsay J; Henry, Michael; Smith, Christine M.; Halperin, Daniel; Brady, Jessica; Brennan, Bernadette; Senchenko, Maria Anatolevna; Reeves, Marie; Hoppe, Bradford S.; Terezakis, Stephanie; Talaulikar, Dipti; Picardi, Marco; Kirova, Youlia; Fergusson, Paige; Hawkes, Eliza A.; Lee, Denise; Doo, Nicole Wong; Barraclough, Allison; Cheah, Chan Y.; Ku, Matthew; Hamad, Nada; Mutsando, Howard; Gilbertson, Michael; Marconi, Tamara; Viiala, Nicholas; Maurer, Matthew J; Eichenauer, Dennis A; Hoppe, Richard T.; Borchmann, Peter; Fuchs, Michael; Hartmann, Sylvia; Eich,; Department of Radiation Oncology, Stanford School of Medicine, Stanford University, Stanford, CA; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; BC Cancer, Vancouver, Canada; King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; The University of Texas MD Anderson Cancer Center, Houston, TX; Oxford University, Oxford, United Kingdom; Peter MacCallum Cancer Centre, Melbourne, Australia; Princess Margaret Cancer Centre, Toronto, Canada; The University of Chicago, Chicago, IL; Duke University, Durham, NC; Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Dana-Farber Cancer Institute, Boston, MA; University of Rochester, Rochester, NY; University of Pennsylvania, Philadelphia, PA; Yale University, New Haven, CT; The Royal Hospital, Muscat, Oman; Tom Baker Cancer Centre, Calgary, Canada; Department of Oncology, University of Turin, Turin, Italy; Roswell Park Comprehensive Cancer Cent; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.42, 2024, pp.2271-2280)
-
146
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
- Tarantino, Paolo; Tayob, Nabihah; Villacampa, Guillermo; Dang, Chau; Yardley, Denise A.; Isakoff, Steven J.; Valero, Vicente; Faggen, Meredith; Mulvey, Therese; Bose, Ron; Weckstein, Douglas; Wolff, Antonio C.; Reeder-Hayes, Katherine; Rugo, Hope S.; Ramaswamy, Bhuvaneswari; Zuckerman, Dan; Hart, Lowell; Gadi, Vijayakrishna K.; Constantine, Michael; Cheng, Kit; Garrett, Audrey Merrill; Marcom, P. Kelly; Albain, Kathy; DeFusco, Patricia; Tung, Nadine; Ardman, Blair; Nanda, Rita; Jankowitz, Rachel C.; Rimawi, Mothaffar; Abramson, Vandana; Pohlmann, Paula R.; Van Poznak, Catherine; Forero-Torres, Andres; Liu, Minetta C.; Ruddy, Kathryn J.; Waks, Adrienne G.; DeMeo, Michelle; Burstein, Harold J.; Partridge, Ann H.; Dell'Orto, Patrizia; Russo, Leila; Krause, Emma; Newhouse, Daniel J.; Kurt, Busem Binboğ a; Mittendorf, Elizabeth A.; Schneider, Bryan; Prat, Aleix; Winer, Eric P.; Krop, Ian E.; Tolaney, Sara M.; Barroso-Sousa, Romualdo; C; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; SOLTI Breast Cancer Research Group, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Harvard Medical School, Boston, MA; MD Anderson Cancer Center, Houston, TX; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Washington University School of Medicine, St Louis, MO; New Hampshire Oncology Hematology, Manchester, NH; Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of California, San Francisco, CA; Ohio State University Comprehensive Cancer Center, Columbus, OH; St Luke's Mountain States Tumor Institute, Boise, ID; Wake Forest Baptist Health, Winston-Salem, NC; University of Illinois Cancer Center, Chicago, IL; Medical Oncology, Dan; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.42, 2024, pp.3652-3665)
QUICK MENU
